pI: 6.4849 |
Length (AA): 170 |
MW (Da): 18864 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 5 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
46 | 130 | 2cqc (A) | 104 | 197 | 36.00 | 0 | 1 | 0.8195 | 0.13 |
50 | 147 | 2mkc (A) | 8 | 105 | 34.00 | 0.00025 | 0.99 | 1.07677 | -0.74 |
51 | 129 | 2x1f (A) | 16 | 94 | 22.00 | 0.005 | 0.65 | 0.836006 | -0.99 |
55 | 115 | 1cvj (B) | 101 | 159 | 27.00 | 0 | 0.9 | 0.583324 | 0.08 |
68 | 110 | 4yud (A) | 168 | 210 | 40.00 | 0.043 | 0.25 | 0.583041 | 0.84 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | Bloodstream Form. | Siegel TN |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | Procyclic. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_128283)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT3G47120 | RNA recognition motif and zinc finger domain-containing protein |
Babesia bovis | BBOV_IV005060 | RNA-binding protein, putative |
Brugia malayi | Bm1_02690 | RNA binding motif protein |
Brugia malayi | Bm1_24695 | hypothetical protein |
Candida albicans | CaO19.8647 | RRM-containing orf similar to S. cerevisiae YIR005W |
Candida albicans | CaO19.1045 | RRM-containing orf similar to S. cerevisiae YIR005W |
Caenorhabditis elegans | CELE_C30B5.4 | Protein C30B5.4 |
Cryptosporidium parvum | cgd6_3490 | RNA-binding protein, putative |
Dictyostelium discoideum | DDB_G0294559 | RNA recognition motif-containing protein RRM |
Drosophila melanogaster | Dmel_CG10466 | CG10466 gene product from transcript CG10466-RB |
Echinococcus granulosus | EgrG_000667300 | RNA binding motif protein 2 |
Entamoeba histolytica | EHI_169910 | RNA recognition motif domain containing protein |
Echinococcus multilocularis | EmuJ_000667300 | RNA binding motif protein 2 |
Homo sapiens | ENSG00000134597 | RNA binding motif protein, X-linked 2 |
Leishmania braziliensis | LbrM.26.0770 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_260730.1 | RNA recognition motif. (a.k.a. RRM, RBD, or RNP domain), putative |
Leishmania infantum | LinJ.26.0730 | hypothetical protein, conserved |
Leishmania major | LmjF.26.0760 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.26.0760 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_03303 | hypothetical protein |
Mus musculus | ENSMUSG00000031107 | RNA binding motif protein, X-linked 2 |
Neospora caninum | NCLIV_024340 | hypothetical protein |
Oryza sativa | 4334639 | Os03g0826400 |
Plasmodium berghei | PBANKA_0805800 | RNA-binding protein, putative |
Plasmodium falciparum | PF3D7_0319500 | RNA-binding protein, putative |
Plasmodium knowlesi | PKNH_0821700 | RNA-binding protein, putative |
Plasmodium vivax | PVX_095260 | RNA-binding protein, putative |
Plasmodium yoelii | PY00973 | RNA recognition motif, putative |
Saccharomyces cerevisiae | YIR005W | Ist3p |
Schistosoma japonicum | Sjp_0109550 | RNA-binding motif protein, X-linked 2, putative |
Schistosoma mansoni | Smp_170230 | rna recognition motif containing protein |
Schmidtea mediterranea | mk4.001427.01 | RNA-binding motif protein, X-linked 2 |
Trypanosoma brucei gambiense | Tbg972.7.1150 | RNA-binding protein, putative |
Trypanosoma brucei | Tb927.7.1180 | RNA-binding protein, putative |
Trypanosoma congolense | TcIL3000_7_830 | RNA-binding protein, putative |
Trypanosoma cruzi | TcCLB.508213.20 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.507515.60 | hypothetical protein, conserved |
Toxoplasma gondii | TGME49_263595 | RNA-binding protein |
Theileria parva | TP01_0238 | RNA-binding protein, putative |
Trichomonas vaginalis | TVAG_365450 | RNA recognition motif containing protein, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.7.1180 this record | Trypanosoma brucei | significant gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.7.1180 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.7.1180 this record | Trypanosoma brucei | significant gain of fitness in procyclic forms | alsford |
Tb927.7.1180 this record | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_C30B5.4 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_C30B5.4 | Caenorhabditis elegans | larval arrest | wormbase |
CELE_C30B5.4 | Caenorhabditis elegans | sterile | wormbase |
PBANKA_0805800 | Plasmodium berghei | Essential | plasmo |
TGME49_263595 | Toxoplasma gondii | Probably essential | sidik |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | increased (PATO:0000470) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | increased cell proliferation (significant gain of fitness) in bloodstream forms (stage 3 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | normal (PATO:0000461) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | increased (PATO:0000470) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | increased cell proliferation (significant gain of fitness) in procyclic forms . | References: | 21363968 | |
cell proliferation (GO:0008283) | normal (PATO:0000461) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
1 literature reference was collected for this gene.